Keyphrases
HPV16
100%
Human Papillomavirus Types
100%
Human Papillomavirus Vaccine
100%
Type Replacement
100%
Neutralizing Antibodies
46%
Unvaccinated
38%
HPV18
38%
Quadrivalent Vaccine
38%
High-risk Human Papillomavirus (HR-HPV)
30%
Community-randomized Trials
30%
High Risk
23%
Vaccination Coverage
23%
Vaccine Response
23%
Bivalent Vaccine
23%
Vaccination
15%
Revaccination
15%
Seroprevalence
15%
Oncogenic Human Papillomavirus
15%
Gender-neutral Vaccination
15%
HPV31
15%
Active Follow-up
15%
Genotype Replacement
15%
Cross-neutralizing Antibody
15%
HPV68
15%
Indirect Impacts
7%
Direct Impact
7%
Cervical Cancer
7%
High Prevalence
7%
Population-based
7%
Control Arm
7%
Cumulative Incidence
7%
Transmission Dynamics
7%
Seroconversion
7%
Birth Cohort
7%
Trial Participants
7%
Biobank
7%
Vaccination Strategy
7%
Sufficient Cause
7%
Gender Neutral
7%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
7%
Human Papillomavirus Genotypes
7%
Pre-vaccination
7%
HPV58
7%
Serotype Replacement
7%
Maternity
7%
Vaccine Target
7%
Risk-taking
7%
Non-vaccine Types
7%
Population-representative
7%
Cross-protective
7%
Vaccine Impact
7%
Early Indication
7%
Anogenital Cancer
7%
Immunology and Microbiology
Wart Virus
100%
Human Papillomavirus Type 16
85%
Neutralizing Antibody
42%
Human Papillomavirus Type 18
42%
Prevalence
28%
Cervarix
28%
Arm
21%
Antibody Response
21%
Seroprevalence
14%
Human Papillomavirus Type 31
14%
Dynamics
7%
Infectious Agent
7%
Serotype
7%
Seroconversion
7%
Human Papillomavirus Type 58
7%
Hepatitis B Virus
7%
Human Papillomavirus Type 51
7%